Skytrofa

Active Ingredient(s): Lonapegsomatropin-tcgd
FDA Approved: * August 25, 2021
Pharm Company: * ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S
Category: Growth Hormone Treatment

Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1] Lonapegsomatropin is a prodrug of somatropin.[1] Lonapegsomatropin was approved for medical use in the United States in August 2021.[1][2][3] Contents 1 Medical uses 2 References 3 Further reading 4 External links Medical uses Lonapegsomatropin is a growth hormone therapy ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Skytrofa 3 mg Subcutaneous Injection, Powder, Lyophilized, for Solution
NDC: 73362-003
Labeler:
Ascendis Pharma Endocrinology, Inc.
Skytrofa 3.6 mg Subcutaneous Injection, Powder, Lyophilized, for Solution
NDC: 73362-004
Labeler:
Ascendis Pharma Endocrinology, Inc.
Skytrofa 4.3 mg Subcutaneous Injection, Powder, Lyophilized, for Solution
NDC: 73362-005
Labeler:
Ascendis Pharma Endocrinology, Inc.
Skytrofa 5.2 mg Subcutaneous Injection, Powder, Lyophilized, for Solution
NDC: 73362-006
Labeler:
Ascendis Pharma Endocrinology, Inc.
Skytrofa 6.3 mg Subcutaneous Injection, Powder, Lyophilized, for Solution
NDC: 73362-007
Labeler:
Ascendis Pharma Endocrinology, Inc.
Skytrofa 7.6 mg Subcutaneous Injection, Powder, Lyophilized, for Solution
NDC: 73362-008
Labeler:
Ascendis Pharma Endocrinology, Inc.
Skytrofa 9.1 mg Subcutaneous Injection, Powder, Lyophilized, for Solution
NDC: 73362-009
Labeler:
Ascendis Pharma Endocrinology, Inc.
Skytrofa 11 mg Subcutaneous Injection, Powder, Lyophilized, for Solution
NDC: 73362-010
Labeler:
Ascendis Pharma Endocrinology, Inc.
Skytrofa 13.3 mg Subcutaneous Injection, Powder, Lyophilized, for Solution
NDC: 73362-011
Labeler:
Ascendis Pharma Endocrinology, Inc.